Mighty Morphin’ Small Molecules
New method to control polymorphism could see “widespread use across the pharma industry”
James Strachan | | Quick Read
Polymorphism is a well-established phenomenon whereby chemical compounds exist in multiple crystalline forms. These forms can differ in terms of solubility, melting point, and other basic properties, which can affect the bioavailability of drugs. Naturally, controlling polymorphism is of interest to pharma developers – the more forms chemists can produce, the greater the possibilities.
Researchers from the University of Montreal, Canada, have uncovered a method of searching for polymorphs based on mixed-crystal seeds (1). Using the approach, the team produced new crystalline forms of the small molecule ROY – which is used to synthesize antipsychotic drug Olanzapine.
“The method promises to become a valuable tool for polymorphic screening in all fields where crystalline solids are used,” according to the authors. Meanwhile, Susan Reutzel-Edens, a senior research advisor at Eli Lilly, has reportedly said the platform is “likely to see widespread use across the pharmaceutical industry” (2).
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine